News

Article

Pharmaceutical Technology

Pharmaceutical Technology-10-02-2011
Volume35
Issue 10

Q&A with Rao Tatapudy, Catalent

A Q&A with Rao Tatapudy, vice-president of scientific affairs at Catalent, on recent industry trends.

PharmTech:

What is the biggest industry challenge you're now facing?

Tatapudy:

The productivity and efficiency of internal drug development have become big challenges in the industry. These challenges arise from the large size of a few Big Pharma companies (which results from consolidation), the emergence of several large generic-drug players, long approval times for both branded and generic products, and a short patent life for new drugs. This situation is an opportunity for global drug-development and delivery companies that support the pharmaceutical industry. By offering support for a product's entire life cycle, including preformulation, product development, clinical supplies, commercialization, analytical services, packaging services, and regulatory support, these companies can position themselves to succeed in the current environment.

PharmTech:

Do you see a new industry trend emerging?

Tatapudy:

Yes. Big Pharma is struggling with extensive talent on hand and limited product-development budgets, partly because of mergers and acquisitions, and partly because fewer and fewer new drug applications are being filed each year. On the other hand, global drug-development and delivery companies are extremely enthusiastic about the prospects for growth and innovation and have expanded their horizons to serve the entire industry across most dosage forms. In particular, because a large majority of new molecules in development are BCS class II and IV compounds with significant bioavailability challenges, highly specialized expertise in drug development, delivery, and manufacturing will be needed, and this situation will require drug innovators to work closely with specialty drug delivery companies such as Catalent.

PharmTech:

What is the most common demand your clients are currently making of you?

Tatapudy:

Our customers approach us for more products, better treatments, reliably supplied. Many customers come to Catalent for help in solving their bioavailability, solubility, and permeability challenges.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content